Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "heart-failure"

98 News Found

Ceryx Medical raises £3.8m in seed funding to bring cardiac device to in-human trials
Startup | April 28, 2022

Ceryx Medical raises £3.8m in seed funding to bring cardiac device to in-human trials

Cysoni is a bionic device that paces the heart with real-time respiratory modulation


Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Biotech | April 05, 2022

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)


Bayer to invest €1.3 billion for driving innovations in life sciences, agriculture segment
News | April 03, 2022

Bayer to invest €1.3 billion for driving innovations in life sciences, agriculture segment

Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024


JBCPL buys Azmarda trademark for India at Rs 246 crore
News | April 03, 2022

JBCPL buys Azmarda trademark for India at Rs 246 crore

The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.


Dr. Reddy's to acquire cardiovascular brand Cidmus in India
News | April 01, 2022

Dr. Reddy's to acquire cardiovascular brand Cidmus in India

The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction


New spesolimab data show promising results in patients with generalised pustular psoriasis flares
Biotech | March 28, 2022

New spesolimab data show promising results in patients with generalised pustular psoriasis flares

Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status


Zydus’ OxemiaTM receives approval from DCGI to treat Anaemia associated with Chronic Kidney Disease
Drug Approval | March 07, 2022

Zydus’ OxemiaTM receives approval from DCGI to treat Anaemia associated with Chronic Kidney Disease

OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)


AstraZeneca and Neurimmune enter licencing agreement to develop and commercialise NI006
Biotech | March 01, 2022

AstraZeneca and Neurimmune enter licencing agreement to develop and commercialise NI006

Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m


LivaNova announces first patient implanted in OSPREY clinical study
Medical Device | February 27, 2022

LivaNova announces first patient implanted in OSPREY clinical study

Study to evaluate effectiveness of hypoglossal nerve stimulation


Zydus receives USFDA approval for Dapagliflozin tablets
Drug Approval | February 23, 2022

Zydus receives USFDA approval for Dapagliflozin tablets

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad